Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Run-in period

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    785 result(s) found for: Run-in period. Displaying page 1 of 40.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-005174-11 Sponsor Protocol Number: U1111-1166-6923 Start Date*: 2015-10-01
    Sponsor Name:Uppsala University Hospital
    Full Title: A randomized, double-blinded placebo-controlled, paralleled designed, investigator sponsored study of the effect of the GLP-1 receptor agonist liraglutide on beta-cell function in C-peptide positiv...
    Medical condition: Beta-cell function in C-peptide positive type 1 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003174-17 Sponsor Protocol Number: GA1405 Start Date*: 2015-03-24
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A multicentre, randomised, double-blind, two arm, parallel group, placebo controlled pivotal study to assess the effect of a sodium alginate liquid suspension as add-on therapy in GORD patients wit...
    Medical condition: Gastro-Oesophageal Reflux Disease (GORD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003701-25 Sponsor Protocol Number: 7035-CL-0014 Start Date*: 2013-12-09
    Sponsor Name:Tacurion Pharma Inc
    Full Title: A Phase II, Multicenter,Randomization, Double-Blind, Parallel Group, Placebo-Controlled, Forced Titration Proof of Concept Study to Assess Efficacy, Safety, Tolerability and the Therapeutic Ratio ...
    Medical condition: Nocturia associated with nocturnal polyuria
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064016 Nocturnal polyuria LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004543-57 Sponsor Protocol Number: D9618C00001 Start Date*: 2006-03-29
    Sponsor Name:AstraZeneca AB
    Full Title: A 6-month randomized, double-blind, parallel-group, multicentre, placebo-controlled Phase II study to compare anti-asthmatic effect and safety of esomeprazole (Nexium) 40 mg twice daily or 40 mg on...
    Medical condition: Moderate to severe asthma and symptoms of gastroesophageal reflux disease (GERD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) IT (Completed) SK (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001193-25 Sponsor Protocol Number: D9830C00003 Start Date*: 2006-09-21
    Sponsor Name:AstraZeneca AB
    Full Title: A 4 week randomised, double blind, placebo controlled, parallel group, phase II, PoP study to assess the efficacy and safety of AZD1981 in adult patients with asthma.
    Medical condition: Asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004470-25 Sponsor Protocol Number: GA1214 Start Date*: 2013-01-08
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A multicentre, randomised, double-blind, two arm, parallel group, pilot study to assess the effect of Gaviscon® Double Action Mint as add-on therapy in GORD patients with inadequate response to onc...
    Medical condition: Patients with Gastro Oesophageal Reflux Disease (GORD) with inadequate response to PPI treatment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000894-56 Sponsor Protocol Number: NAK-06 Start Date*: 2014-02-26
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: A 12-week double-blind, randomised, placebo-controlled, parallel group phase III study, followed by a 4-week randomised withdrawal period to evaluate the efficacy and safety of oral ibodutant 10 mg...
    Medical condition: Irritable bowel syndrome with diarrhoea (IBS-D) in female patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    18.0 100000004856 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) IT (Completed) DE (Completed) ES (Completed) GB (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-002144-33 Sponsor Protocol Number: RLM-MD-04 Start Date*: 2018-11-06
    Sponsor Name:Allergan Ltd.
    Full Title: A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Completed) FR (Completed) BE (Completed) BG (Prematurely Ended) DK (Completed) AT (Prematurely Ended) LV (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002441-30 Sponsor Protocol Number: TV48125-CNS-30068 Start Date*: 2017-12-19
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Mig...
    Medical condition: episodic and chronic migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027603 Migraine headaches HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) SE (Completed) BE (Completed) DE (Completed) CZ (Completed) FI (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004307-30 Sponsor Protocol Number: IXA-CSP-001 Start Date*: 2017-03-30
    Sponsor Name:IXALTIS
    Full Title: A Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Phase II, Dose Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of oral Litoxetine 10mg, 20mg and 40mg Twice Daily (BI...
    Medical condition: Mixed Urinary Incontinence
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000940-26 Sponsor Protocol Number: CASM981C2314 Start Date*: 2004-09-24
    Sponsor Name:Novartis Pharma
    Full Title: A 22-week randomized, multicenter, parallel-group, double-blind study to compare a pimecrolimus 1 % (Elidel) twice daily (b.i.d.) maintenance dosing regimen to a once daily (o.d.) maintenance dosin...
    Medical condition: Atopic dermatitis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002177-20 Sponsor Protocol Number: RLM-MD-02 Start Date*: 2018-11-06
    Sponsor Name:Allergan Ltd.
    Full Title: A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) LV (Prematurely Ended) HU (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended) AT (Completed) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004549-23 Sponsor Protocol Number: TV48125-CNS-30049 Start Date*: 2016-11-24
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for...
    Medical condition: Chronic Migraine
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10066636 Chronic migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Completed) FI (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003534-27 Sponsor Protocol Number: CIGE025B1301 Start Date*: 2016-02-16
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A 24 Week, Open Label, Multi-center Evaluation of Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic ...
    Medical condition: Allergic asthma
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-005173-27 Sponsor Protocol Number: 0858A4-318-WW Start Date*: 2005-10-21
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF A COMBINATION OF LEVONORGESTREL AND ETHINYL ESTRADIOL IN A CONTINUOUS DAILY REGIMEN IN SUBJECTS WITH PREMENSTRUAL DYSPHORIC DISO...
    Medical condition: Premenstrual dysphoric disorder (PMDD) affects 3% to 5% of menstruating women. PMDD is defined by markedly depressed mood, anxiety, and/or affective lability during the last week of the late lutea...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) FI (Completed) SE (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003553-82 Sponsor Protocol Number: AGI003-003 (ARDIS-1) Start Date*: 2007-10-22
    Sponsor Name:AGI Therapeutics Research Ltd
    Full Title: A Randomized, Double-blind, Placebo-controlled Study of AGI-003 (Arverapamil) in the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
    Medical condition: Irritable Bowel Syndrome with Diarrhea (IBS-D)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005848-21 Sponsor Protocol Number: M11-352 Start Date*: 2013-12-18
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy SONAR: Stud...
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) BE (Prematurely Ended) GB (Completed) IE (Completed) PT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) GR (Completed) SK (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005486-21 Sponsor Protocol Number: GA1102 Start Date*: 2012-01-26
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd.
    Full Title: A multicentre, randomised, double-blind, two arm, parallel group, placebo controlled, pilot study to assess the effect of Gaviscon Advance as add-on therapy in GORD patients with inadequate respons...
    Medical condition: Gastro Oesophageal Reflux Disease (GORD)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004856 10066874 Gastroesophageal reflux disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002463-88 Sponsor Protocol Number: L00133 IV 301 (ORF) Start Date*: 2006-07-18
    Sponsor Name:Orfagen
    Full Title: Efficacy and safety of a human normal immunoglobulin product for intravenous administration (IVIg) in the treatment of dermatomyositis (DM) and polymyositis (PM): prospective, randomised, double-bl...
    Medical condition: Idiopathic DM and PM with insufficiently improved muscle strength under conventional therapy (Glucocorticosteroids associated with immunosuppressors).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-000895-14 Sponsor Protocol Number: NAK-07 Start Date*: 2014-01-27
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: A 52-week, double-blind, randomised, placebo-controlled, parallel-group phase III study with re-randomisation at week 25 to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in f...
    Medical condition: Irritable bowel syndrome with diarrhoea (IBS-D) in female patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    18.0 100000004856 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Prematurely Ended) SE (Prematurely Ended) LV (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) DE (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 22:56:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA